Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Other Non Operating Income (2016 - 2025)

Ligand Pharmaceuticals' Other Non Operating Income history spans 16 years, with the latest figure at $500000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 98.21% year-over-year to $500000.0; the TTM value through Dec 2025 reached $2.3 million, up 117.99%, while the annual FY2024 figure was -$15.1 million, N/A changed from the prior year.
  • Other Non Operating Income for Q3 2025 was $500000.0 at Ligand Pharmaceuticals, down from $1.4 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $27.9 million in Q3 2024 and bottomed at -$33.5 million in Q2 2024.
  • The 5-year median for Other Non Operating Income is $551500.0 (2023), against an average of -$362722.2.
  • The largest annual shift saw Other Non Operating Income skyrocketed 960.73% in 2021 before it tumbled 3739.98% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at $5.5 million in 2021, then crashed by 114.38% to -$793000.0 in 2022, then surged by 676.29% to $4.6 million in 2023, then crashed by 258.49% to -$7.2 million in 2024, then soared by 106.9% to $500000.0 in 2025.
  • Per Business Quant, the three most recent readings for LGND's Other Non Operating Income are $500000.0 (Q3 2025), $1.4 million (Q2 2025), and $443000.0 (Q1 2025).